• 1
    Lauer GM, Walker BD. Hepatitis C virus infection. New Engl J Med 2001; 345: 4152.
  • 2
    Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl.): 3546.
  • 3
    Craxi A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis 2003; 23 (Suppl. 1): 3546.
  • 4
    Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 37081.
  • 5
    Simmonds P. Viral heterogeneity of hepatitis C virus. J Hepatol 1999; 31 (Suppl.): 5460.
  • 6
    Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominga T, Persing DH. Hepatitis C genotypes in the United States: epidemiology, pathogenesis, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 6349.
  • 7
    Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999; 58: 448.
  • 8
    Keefe EB. Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Semin Liver Dis 2003; 23 (Suppl 1): 12.
  • 9
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 95865.
  • 10
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 11
    National Institutes of Health. NIH Consensus Development Conference Statement. Proceedings of the Management of Hepatitis C; 2002, June 10–12; Bethesda MD. Gastroenterology 2002; 123: 208299.
  • 12
    Moher D, Cook DJ, Eastwood S, Olkin I, Rennei D, Stroup DF. Improving the quality of reports of meta-analysis of randomized controlled trials: the QUOROM statement. Lancet 1999; 354: 1896900.
  • 13
    Petitti DB. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis, 2nd edn. New York: Oxford University Press, 2000.
  • 14
    Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282: 105460.
  • 15
    Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 16
    Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 62934.
  • 17
    Cucherat M, Boissel JP, Leizorovicz A. EasyMA: a program for the meta-analysis of clinical trials. Comput Methods Programs Biomed 1997; 53: 18790.
  • 18
    Esmat G, Abouzied AM, Adel-Aziz F, Strickland T. Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin. Hepatology 2003; 38: 324A.
  • 19
    Shobokshi OA, Serebour FE, Skakni L, Al Khalifa M. Combination therapy of peginterferon alfa-2a and ribavirin significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia. Hepatology 2003; 38: 996A.
  • 20
    Thakeb FAI, Omar MM, El Awady MM, Isshak SY. Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus genotype 4 among Egyptian patients. Abstract 37, Proceedings of the 54th Annual Meeting of the AASLD, Boston, MA, October 24–28, 2003.
  • 21
    Faleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Proceedings of the Emirates Pan-Arab Gastroenterology Week, Sharjah, UAE, January 13–17, 2004.
  • 22
    Castera L, Morice Y, Grando V, Bon C, Deny P, Roulot L. Le virus de l'hépatite C de génotype4. caractérristiques épidémiologiques et résponse aux traitements antiviraux. Gastroenterol Clin Biol 2003; 27: 596604.
  • 23
    Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotype 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 2835.
  • 24
    Pawlotsky J-M, Hezode C, Pellegrin B, et al. Early HCV genotype 4 replication kinetics during treatment with peginterferon alfa-2a (Pegasys)-ribavirin combination. A comparison with HCV genotype 1 and 3 kinetics. Hepatology 2002; 36: 291A.
  • 25
    Ferenci P. Weight-based dosing of pegylated interferon alfa in chronic hepatitis C-Just a marketing ‘gag’? Dig Liver Dis 2003; 35: 6016.
  • 26
    Hassan F, Asker H, Al-Khaldi J, et al. Pegylated interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis genotype 4. Hepatology 2003; 38: 982A.
  • 27
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 28
    Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F. Optimized virological response in hepatitis C virus genotype 4 with peginterferon alfa-2a and ribavirin (letter). Ann Intern Med 2004; 140: 723.